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Abstract
Background: Population aging increases the number of glaucoma patients which leads to higher workloads of
glaucoma specialists. If stable glaucoma patients were monitored by optometrists and ophthalmic technicians in a
glaucoma follow-up unit (GFU) rather than by glaucoma specialists, the specialists’ workload and waiting lists might
be reduced.
We compared costs and quality of care at the GFU with those of usual care by glaucoma specialists in the Rotter-
dam Eye Hospital (REH) in a 30-month randomized clinical trial. Because quality of care turned out to be similar,
we focus here on the costs.
Methods: Stable glaucoma patients were randomized between the GFU and the glaucoma specialist group. Costs
per patient year were calculated from four perspectives: those of patients, the Rotterdam Eye Hospital (REH), Dutch
healthcare system, and society. The outcome measures were: compliance to the protocol; patient satisfaction;
stability according to the practitioner; mean difference in IOP; results of the examinations; and number of
treatment changes.
Results: Baseline characteristics (such as age, intraocular pressure and target pressure) were comparable between
the GFU group (n = 410) and the glaucoma specialist group (n = 405).
Despite a higher number of visits per year, mean hospital costs per patient year were lower in the GFU group
(€139 vs. €161). Patients’ time and travel costs were similar. Healthcare costs were significantly lower for the GFU
group (€230 vs. €251), as were societal costs (€310 vs. €339) (p < 0.01). Bootstrap-, sensitivity- and scenario-analyses
showed that the costs were robust when varying hospital policy and the duration of visits and tests.
Conclusion: We conclude that this GFU is cost-effective and deserves to be considered for implementation in
other hospitals.
Background
Glaucoma is a group of eye diseases characterized by
damage to the optic nerve that causes gradual, irreversi-
ble visual field loss. It is often related to high intraocular
pressure (IOP) and age. Usual care for glaucoma
patients consists of diagnosis, lifelong monitoring and
treatment, and in most countries is currently provided
by glaucoma specialists.
Ophthalmic care in the Netherlands is currently being
challenged by a high workload for glaucoma specialists
and long waiting lists. Due to ageing of the population,
the prevalence of glaucoma probably will increase
strongly over time [1], possibly endangering access to
glaucoma care as currently provided. Task substitution
may be one way to ease this problem.
Stable glaucoma patients and patients with a risk fac-
tor for developing glaucoma may not require care by a
glaucoma specialist. Instead, monitoring by hospital
optometrists or ophthalmic technicians may be suffi-
cient. This would leave glaucoma specialists with more
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time for complex cases and new glaucoma patients, allo-
cating their expertise more efficiently, and also reducing
waiting lists. As optometrists and ophthalmic techni-
cians are less expensive per hour than specialists, such
task substitution might save costs.
To date, only one study [2-6] presented information
about the efficiency of substitution in glaucoma care,
and its consequences for both quality of care and cost-
effectiveness. However, that study compared care by
glaucoma specialists with that by community optome-
trists rather than hospital optometrists. It concluded
that glaucoma monitoring by community optometrists is
effective, but not cost-effective in most situations. The
outcomes were similar to those in specialist care, and
the patients were satisfied. However, because of a (stan-
dard) shorter follow-up interval than in specialist care,
community monitoring was more expensive [6].
We therefore conducted a randomized controlled trial
(RCT) to determine the cost-effectiveness of shared care
in stable glaucoma patients in a hospital setting. We
compared usual care by glaucoma specialists and the
care provided by optometrists and ophthalmic techni-
cians within a glaucoma follow-up unit (GFU) in the
Rotterdam Eye Hospital (REH) in terms of costs and
quality of care.
Because this paper focuses on the costs of the glau-
coma care related to important aspects of the quality of
care, we also measured patient satisfaction, the number
of treatment changes, the change in IOP and the com-
pliance to the standard working protocol. The quality of
care is described in more detail elsewhere. [7].
Methods
Randomized Controlled Trial
Patients who visited a glaucoma specialist or the GFU
between September 2005 and April 2006 were invited to
participate. The RCT was explained and written infor-
mation was provided to them. The study was approved
by the Review Board of Erasmus MC.
To be eligible for the study, patients had to meet the
following criteria:
(1) the patient was diagnosed with stable glaucoma in
one or both eyes (the next visit scheduled in 6 months
or more) or had a risk factor for glaucoma, i.e. high IOP
and/or a positive family history. Eyes were considered to
be glaucomatous if they had typical thinning or notching
of the neuroretinal rim of the optic nerve head, with or
without disc haemorrhages, visual field defects, peripa-
pillary atrophy and/or and elevated IOP;
(2) a glaucoma specialist of the REH referred the
patient to the GFU;
(3) the actual ophthalmic medication and the target
pressure (TP) was recorded in the medical record. The
target pressure was determined by the individual
clinicians in all patients, where they took in considera-
tion: the age of the patient, the appearance of the optic
disc, the level of intraocular pressure, any co-morbidity
and any other risk factors. For patients with a risk factor
for glaucoma, the TP was by default 30 mmHg, unless
other risk factors called for an explicitly lower TP;
(4) an examination of the optic disc, macula, and the
fundus periphery was performed;
(5) the Snellen visual acuity in each eye was ≥ 20/100
and/or the patient had no visual field loss within the
central 10°, as measured by a Humphrey Field Analyser,
standard 24-2 test algorithm (HFA 24-2; Carl Zeiss
Meditec, Dublin, CA, USA);
(6) the refractive error was between +5 and -8 diop-
tres (spherical equivalent);
(7) no other significant ocular disease was present;
(8) the patient had not undergone laser therapy for
diabetic retinopathy.
Once the glaucoma specialist decided that the patient
was suitable for the GFU, the patient was randomly allo-
cated to a treatment group. In the glaucoma specialist
group, the patients received care of glaucoma specialists
and residents only. In the GFU group the patient visited
the GFU twice followed by a visit to the glaucoma spe-
cialist or resident if the patient was stable. If necessary,
the patient was seen by a glaucoma specialist earlier.
The GFU employees (optometrist or ophthalmic techni-
cian level 1 or 2) provided care according to a standard
working protocol (see Table 1) and under supervision of
glaucoma specialists.
Identification and Randomisation
Glaucoma specialists were asked to provide information
about this study to eligible patients. Eligible patients
were also identified by searching the patient files of the
patients that were already referred by the glaucoma spe-
cialists to the GFU in the months preceding the start of
our study. They received information about the study
during their next visit. All patients that were eligible
and willing to participate were randomly allocated to a
treatment group using a randomisation table. For the
GFU patients that were allocated to the usual care
group an appointment was made with the glaucoma
specialist who referred them to the GFU.
To avoid glaucoma specialists influencing the alloca-
tion of patients, we used central randomisation by the
researchers using stratification by 2 variables: the refer-
ring glaucoma specialist, and the time to the next sched-
uled visit, being either 6 months or more than 6
months.
Outcome measures
The outcome of the treatment was measured every visit.
The outcome measures of the RCT were: 1) compliance
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of the GFU employees to the standard working protocol,
2) patient satisfaction with the following items: a) overall
mark for the received care; b) social interaction with the
health care provider; c) expectations about the visit;
d) perceived knowledge of the health care provider;
e) waiting area, 3) stability according to the practitioner
(whether the time till next visit should be significantly
shorter than the time from the previous visit), 4) mean
difference of the IOP (IOP at baseline vs. IOP at the last
visit (if at least 24 months afterwards), 5) the results of
the examinations and, 6) the number of treatment
changes. We did not use glaucomatous progression as
an outcome measure, because we did not expect this
patient population (with a risk factor for glaucoma or
with stable glaucoma) to progress during the study. The
change in IOP during the study has been used as out-
come measure instead.
Sample size and power analysis
We performed a post-hoc power analysis using our data
to estimate the power (certainty) of our conclusion. We
performed that analysis using two outcome parameters
since quality of care has multiple dimensions: the stabi-
lity of the patient according to the practitioner and the
overall mark regarding patient satisfaction. The power
of the study was > 99% based on the stability outcome
when using 5% as an acceptable difference, and >99%
based on the overall mark when using a difference of
0.5 (on a 1-10 scale) as an acceptable difference between
the treatment groups as well.
Patients and visits
From September 2005 to March 2006, 866 patients were
included of which 46 patients did not visit the hospital
during the study period. Three others could not be
monitored with the GDx and 2 patients withdrew their
informed consent (see Figure 1). The remaining 815
patients had a total of 2100 visits. The average time
between visits was 8.8 months, SD ± 4.0. The mean age
(63 years) and gender (53% women) was similar for the
two treatment groups. There were no significant clinical
imbalances between the groups as well (Table 2).
Table 1 Provided care and criteria for back referral to the glaucoma specialist
Activity GFU Usual care Criteria for back referral
Short history Every visit Every visit
IOP* Every visit Every visit
Medical
prescriptions
Every visit Every visit
Optic disc
assessment
Never Every visit
GDx ECC** Every visit At doctor’s request (approx.
once yearly)
- Suspicion of progression
- In case of first GDxECC: NFI > 35 and/or left/right
asymmetry and/or local defect.
HFA 24-2*** Yearly in moderate to advanced visual
field damage****
OR at doctor’s request
At doctor’s request (approx.
once yearly)
Suspicion of progression
Snellen visual
acuity
Every visit As required, at least once
yearly
Decline in visual acuity of ≥ 2 lines
Overall
judgement
Every visit Every visit
Timing next
appointment
Every visit Every visit
* IOP by Goldmann applanation tonometry
** GDx ECC (Carl Zeiss Meditec, Dublin, CA, USA) scanning laser polarimetric images
*** Humphrey Field Analyser, standard 24-2 test algorithm (HFA 24-2; Carl Zeiss Meditec, Dublin, CA, USA)
**** Criteria mild and moderate/severe visual field damage: the mean deviation (MD) of the last performed visual field was ≤ –5dB
Figure 1 Patient flow chart. GDx = Nerve Fiber Analyser.
Holtzer-Goor et al. BMC Health Services Research 2010, 10:312
http://www.biomedcentral.com/1472-6963/10/312
Page 3 of 11
Study duration
The study duration depended on the allocated treatment
group. Patients who were allocated to the usual care
group on the day of their visit to the GFU, entered the
study at their next visit (to the glaucoma specialist),
whereas patients who were allocated to the GFU group,
entered the study immediately. Therefore, the mean
study duration was longer for the GFU group (1.81
year) than for the usual care group (1.43 year). This dif-
ference was statistically significant (p < 0.001). Hence,
for a better comparison, we will present the costs per
patient year in most tables. The influence of this differ-
ence in study duration on the outcomes is probably
minimal, because no major changes were made to the
protocol over time.
Economic Evaluation
We conducted an RCT to measure the quality of care
delivered by glaucoma specialists and by employees of
the GFU. Alongside this RCT, we calculated the costs of
glaucoma care from four perspectives. The perspectives
used were those of the patient, the REH, the health care
system and the society.
A difference in health outcomes between the GFU
and the usual care group was not expected during this
study, because of the slowly progressive nature of this
disease. A literature review, searching for articles with
glaucoma and co-management or shared care in the
title or abstract, provided evidence of an equal quality
of care by optometrists compared to ophthalmologists
as well. [3,4,8-18] Only one of the articles reported a
variation in individual performances of optometrists,
which makes education and accreditation an essential
prerequisite for co-management. [10] All other articles
reported good quality of care by optometrists, high
levels of agreement between optometrists and a research
clinic reference or ophthalmologists or comparable
inter- and intra-observer variability in optic disc assess-
ments. Therefore we will not present a cost-effective-
ness ratio, but we will discuss the costs in relation to
the quality of care.
Identification of cost items and measurement of the
utilization per cost item
We interviewed health care professionals and patients to
identify relevant cost items in the field of medical con-
sumption, implementation of GFU, and patient time and
travel costs.
During the RCT, the medical procedures performed
and the medication prescribed each visit were recorded
in a case report form. The different types of hospital vis-
its were a visit to: a glaucoma specialist, a resident, and
three types of GFU visits, as there were three different
types of personnel within the GFU (optometrist,
ophthalmic technician level 1, and ophthalmic techni-
cian level 2). Per health care provider, the duration of
10 study related visits was measured. The duration of an
HFA and GDx test were also measured in 10 patients.
Every visit, glaucoma patients were given a question-
naire to report their travelling distance, mode of trans-
port, travelling time, waiting time and working status, in
order to calculate the time and travelling costs. We also
examined the fraction of visits in which the GFU
employees asked a glaucoma specialist for advice over
time. In addition, we performed a logistic regression to
determine which variables influenced the probability of
asking advice.
The substitution of care to the GFU required organi-
zational changes and hence implementation costs (both
initial and structural) within the hospital. To collect this
information, health care providers were interviewed.
Valuation of the cost items
All costs were calculated (in euros, price level 2007)
according to the CVZ (The Health Care Insurance
Board) costing guidelines and previous research in
the REH.
[19] Relevant items from the CVZ costing guidelines
[20,21] were updated and used for the calculation of
patient time costs per hour and travelling costs per
kilometer.
Our cost calculation of hospital costs is based on data
from the internal budget allocation provided by the
Table 2 Characteristics of included patients, by treatment group
Glaucoma Follow-up Unit (n = 405) Usual Care (n = 410)
Gender, % of women 53.8 52.2
Mean age (SD, standard deviation) 63.0 (12.1) 63.1 (11.9)
Mean time till next visit in months (SD) 9.8 (2.9) 9.5 (2.9)
Right eye Left eye Right eye Left eye
Mean intraocular pressure (SD) 18.7 (4.1) 18.5 (4.1) 18.8 (4.2) 18.8 (4.1)
Mean target intraocular pressure (SD) 25.1 (5.2) 25.2 (5.2) 25.2 (5.4) 25.1 (5.4)
SD = Standard Deviation.
Holtzer-Goor et al. BMC Health Services Research 2010, 10:312
http://www.biomedcentral.com/1472-6963/10/312
Page 4 of 11
REH financial administration. This information included
location costs, costs of medical specialists and other per-
sonnel, administrative costs, costs of equipment, over-
head costs and interest. Only for the costs of non-laser
operations was the DBC rate (Diagnosis Treatment
combination- a fixed reimbursement rate for a specific
diagnosis related therapy) in 2007 used as estimate of
the resource costs.
The direct personnel costs were calculated based on
the mean duration for each type of visit. However, the
indirect personnel and overhead costs were calculated
top-down, based on the mean duration of a visit in the
hospital as a whole.
The implementation costs, like internal preparatory
meetings, visits to another Dutch hospital, writing the
standard working protocol and the training of the
employees of the GFU were dominated by personnel
input. These costs were added to the costs of a GFU
visit as implementation costs for the GFU. The initial
implementation costs that were only made before start-
ing the GFU were spread over 5 years. The structural
costs per year were added to the initial implementation
costs per year. The implementation costs per visit were
based on the total number of GFU visits in 2007 (1598
visits) as we expect this number of patients to be a
representation of the number of patients in the near
future.
We calculated the patient costs using the information
of the patient questionnaires combined with the updated
time and travelling costs per unit of time and per kilo-
meter. The results will be expressed as average costs per
patient per study year and average costs per patient.
Sensitivity/scenario analysis
To determine the influence of uncertainty regarding the
duration of visits or tests on the costs per patient year,
we performed the following uni-variate sensitivity
analyses:
1. We varied the duration of the visits within the
range we had measured in our study. This resulted in 4
scenarios:
a. We used the minimum duration for all visits;
b. We used the maximum duration for all visits;
c. We used the minimum duration of visits to the
GFU and the maximum duration for the visits to the
glaucoma specialist and resident;
d. We used the maximum duration of visits to the
GFU and the minimum duration for the visits to the
glaucoma specialist and resident.
2. We used the norm duration of the GDx and HFA
as used by the financial department, instead of the dura-
tion of the GDx and HFA measured in our study.
Furthermore we performed scenario analyses to deter-
mine the effects of plausible policy changes in the (near)
future on the costs. We considered the following
scenarios:
3. No optometrists are working in the GFU. This actu-
ally happened during the course of the study. The direct
personnel costs of visits to optometrists were replaced
by those of the ophthalmic technicians.
4. In the study, the patients in the GFU group visited
the glaucoma specialist (or resident) every third visit, or
earlier if necessary. In this scenario, we calculated the
visit costs if this routine was changed to every fifth visit
(or earlier when necessary). In case of a non stable
patient, we distinguished two scenarios:
a. The patient returned to the GFU as soon as he
was judged as stable by the glaucoma specialist dur-
ing a visit.
b. The patient only returned to the GFU after he
was judged as stable by the glaucoma specialist on
two consecutive visits.
Uncertainty analysis
We performed a bootstrapping analysis on the costs per
patient year and two quality of care parameters, to
show the degree of uncertainty regarding the results.
Since quality of care has different dimensions, we
decided to use two outcome parameters. One clinical
quality parameter: stability according to the practitioner
(stability), and one patient satisfaction parameter: the
overall mark given by the patient. By plotting all boot-
strap replicates in a so-called cost-effectiveness plane
(CE-plane), the uncertainty around the point estimates
of the costs and effects was displayed. In this analysis
individual observations of patients were randomly
drawn from the distribution of patients in both groups
in order to calculate the average costs and quality of
care per treatment group. This was replicated for 2500
times. A CE-plane is an x-y-diagram with the x-axis
representing the difference in quality of care between
the GFU and usual care group and the y-axis represent-
ing the difference in costs.
Statistical analysis
We used Excel for the bootstrapping analysis. SPSS 15.0
was used for all other analyses. In normally distributed
variables, we performed a t-test for independent sam-
ples. If not distributed normally, we performed the para-
metric Mann-Whitney U-test to compare the two
treatment groups. We used bootstrapping for deriving
the 95% confidence intervals around the utilization and
costs because of the non-normal distribution of those
parameters.
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For some visits (29%), information about one or more
items related to patient costs was missing. The travelling
distance could be calculated for every patient, based on
the Zip code as known in the hospital information sys-
tem. If appropriate, the remaining missing values were
replaced by values known from other visits of the same
patient. In all other cases (9%), the mean value of a
comparable group of patients based on gender and age
was imputed to the missing values.
Results
Quality of care
The aspects of quality of care measured in our study
were: compliance to the protocol, patient satisfaction,
stability according to the practitioner, mean difference
of the IOP, results of the examinations and the number
of treatment changes. All these aspects of the quality of
care turned out to be similar for the 2 groups (see also
reference 7) and the substitution of care to the GFU
was successfully implemented.
1. The GFU employees performed the required tests
in at least 98.8% of the visits and referred back to the
glaucoma specialist in 84.4% of the remarkable cases.
2. The patient satisfaction was similar in both groups.
The overall mark of the patient was 8.5 for the GFU
group and 8.4 for the usual care group (p = 0.147).
3. The percentage of visits that were considered
“stable” was 16% in the usual care group and 17% in
the GFU group (p = 0.423)
4. No statistical difference was found between the
two groups in the difference of the IOP during the
study (IOP (≥24 months since baseline) - IOP (at baseline)).
5. The average difference in IOP OD was -0.2 mmHG
in the usual care group and -0.6 mmHG in the GFU
treatment group (p = 0.207). The average difference in
IOP OS was -0.1 mmHg in both groups (p = 0.915).
6. The number of treatment changes was 57 (14%)
in the GFU group and 63 (15%) in the usual care
group (p = 0.603).
7. Patients as well as GFU employees and glaucoma
specialists were pleased with the functioning of the
GFU.
Therefore, the quality of care provided in the GFU
was concluded to be equal to the care provided by the
glaucoma specialists for these stable glaucoma patients.
Hospital perspective
The hospital costs covered hospital visits, diagnostic
procedures and further treatment, but were mainly dri-
ven by the costs of the hospital visits to the glaucoma
specialist, resident or GFU employee (approximately
80%). Table 3 shows the duration and composition of
the unit costs per type of visit. The total annual imple-
mentation costs for starting up the GFU were €4917 for
1598 GFU visits. The implementation costs of the GFU
were added to the GFU visits only.
Table 3 shows that despite their longer duration, GFU
visits were less expensive than those to the glaucoma
specialist. In the usual care group, most visits were paid
to the glaucoma specialist or resident. Patients in the
GFU group visited the glaucoma specialist every third
visit or earlier when a patient was judged not stable.
Therefore, the costs per visit could vary within one
patient and between patients within one treatment
group. The mean costs per hospital visit including GDx
were €83.77 (SD = 30.64) in the usual care group and
€68.34 (SD = 15.66) in the GFU group. This difference
was statistically significant (t-test, p = 0.000).
Table 4 describes the hospital care use per patient
year for the two treatment groups. Although the num-
ber of visits per patient year was slightly higher in the
GFU group (1.65 vs. 1.57), this difference was not statis-
tically significant. In the GFU group, a significantly lar-
ger number of GDx images (1.28 vs. 0.77) and auto-
refractions (0.20 vs. 0.08) was performed and more time
was spent on asking advice (in 24% vs. 10% of the visits).
On the other hand, glaucoma surgery, laser therapy,
medication use and the number of HFA tests did not
statistically differ between the two groups.
The hospital care use has been translated into costs
per patient year for the two treatment groups in
Table 5. The total hospital costs were significantly
higher for the usual care group than for the GFU group,
mainly because of the higher hospital visit costs. The
costs of asking advice were modest, but significantly
higher for the GFU group than for the usual care group,
as was to be expected. The 95% confidence interval for
the difference in total hospital costs as derived from the
bootstrap analysis was €-59 to €-2. The probability that
the GFU reduces hospital costs was 98%.
The proportion of visits by GFU employees needing
advice increased initially from 15% to 20% in 2006 and
then decreased (statistically significant) to 13% in 2007
and 7% in 2008. The proportion of visits requiring advice
was not affected by the total number of visits per patient.
These findings were confirmed by a logistic regression.
The year of the visit was the only variable that signifi-
cantly influenced the probability of asking advice. The
other variables in the regression analysis were: stable/
not stable, visit number, gender, time till next visit and
age. This indicates that the GFU employees got more
experienced over time and therefore needed less advice.
Patient perspective
The patient costs consisted of time and travelling costs
of patients and their accompaniment. Table 5 shows
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that the patient costs per visit were significantly higher
in the usual care group, because of higher time costs
(€80 vs. €88). This was mainly caused by a longer wait-
ing time in the hospital in the usual care group. Patients
in the GFU group spent, on average, 44.6 minutes in the
hospital against 59.4 minutes for the patients in usual
care group (p = 0.000). However, because of a higher
number of visits per patient year in the GFU arm, the
patient costs per patient year were not statistically sig-
nificantly higher anymore. The 95% confidence interval
based on the bootstrapping analysis confirmed this
(€-29 to €12). However, there is still a 78% probability
to reduce patient costs.
Health care perspective
The health care costs consisted of the hospital costs as
described above, and of medication costs. Table 5 shows
the health care costs per patient year. Because of the
comparable medication costs and lower hospital costs in
the GFU group, the total health care costs per patient
year were nearly 10% lower for the GFU group (€230.39
vs. €251.26, p = 0.04). The median cost differ statisti-
cally according to the Mann-Whitney U-test, but the
confidence interval as provided through bootstrapping
does not show a difference in the mean costs (€-76 to
€21). However, the probability of cost reduction is con-
siderable: 87%.
Table 3 The composition of the unit costs per type of hospital visit in € (2007)
Visit
glaucoma specialist
Visit
resident
Visit GFU
Optometrist*
Visit GFU
TOA level
1 **
Visit GFU
TOA level
2***
Costs per visit
Total direct personnel costs 24.36 14.49 19.09 15.05 16.61
Total indirect personnel costs 5.46 5.46 6.59 6.59 6.59
Total overhead costs 29.76 29.76 35.90 35.90 35.90
Implementation costs GFU 0.00 0.00 3.08 3.08 3.08
Total costs excluding GDx 59.58 49.71 64.66 60.62 62.18
Costs GDx**** (fraction performed) 25.00 (0.41) 22.25 (0.36) 3.05 3.05 3.05
Total costs including GDx 84.58 71.96 67.71 63.67 65.23
Mean visit duration (min) 9.06 11.00 20.40 20.40 20.40
*Visit to an optometrist or senior employee
**Visit to an ophthalmic technician level 1
***Visit to an ophthalmic technician level 2
****At the start of the Glaucoma Follow up unit (GFU), a Nerve Fiber Analyser (GDx) was purchased by the Rotterdam Eye Hospital (REH). The costs of the GDx
performed during GFU visits, consists only of the GDx imaging device. In the usual care group, the GDx was performed during an extra visit to the perimetry
department. In that situation, the costs of a GDx image included personnel and overhead costs as well and were €61.61 based on a duration of 13.30 minutes
Table 4 Average hospital care use per patient year for the two treatment groups
GFU Usual
care
95%-CI of
difference
between 2
groups
P-value Costs per unit
(in €)
Hospital visits 1.65 1.57 -0.13 to +0.31 0.158 See Table 2
GDx ECC 1.28 0.77 +0.32 to +0.73 0.000 61.61
HFA 0.10 0.11 -0.11 to +0.07 0.266 158.44
Refractive Unit 0.01 0.05 -0.09 to +0.00 0.002 32.43
Auto-refraction 0.20 0.08 -0.03 to +0.21 0.000 4.64–6.59*
Pachymetry 0.02 0.04 -0.07 to +0.03 0.246 23.17
IOP diurnal curve 0.01 0.02 -0.04 to +0.01 0.109 92.66
Laser treatment 0.002 0.007 -0.02 to +0.01 0.267 78.38
Glaucoma surgery 0.002 0.001 -0.01 to +0.01 0.558 1251.70
Asking advice 0.24 0.10 +0.05 to +0.26 0.000 8.19–15.86**
Proportion patients using medication 0.57 0.59 -0.17 to +0.15 0.614 2.53–18.82***
GFU = Glaucoma Follow-up Unit; CI = confidence interval; GDx ECC = Nerve Fiber Analyser Enhanced Corneal Compensation; HFA = Humphrey Field Analyser;
IOP = Intra Ocular Pressure
*Depending on health care provider
**Costs per advice, depending on the health care providers involved
***Costs per month
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Societal perspective
In the societal perspective all costs were taken into
account. It consisted of hospital costs, medication and
patient costs, for 46%, 28% and 26% respectively. The
total societal costs per patient year were almost 10%
higher in the usual care group (Table 5: €339.13 vs.
€310.05, p = 0.009). The mean difference in the total
societal costs per patient year was €-36 (the GFU group
was less expensive). The 95% confidence interval based
on bootstrapping for this difference ranged from €-92 to
€23. Thus, though the median costs per patient year dif-
fers between the two groups, the mean total costs are not
statistically different. This is because the non-normal dis-
tribution of the societal costs. However, the probability
that the GFU saves societal costs is 84% to 89% (see para-
graph about the uncertainty analysis below).
Sensitivity/scenario analysis
Analysis 1: duration of visit
The mean duration of the visits to the glaucoma specia-
list was 9 minutes (ranging from 7 to 11 minutes), to the
resident 11 minutes (ranging from 9 to 13 minutes) and
to the GFU 20 minutes (ranging from 16 to 24 minutes).
In the base case - the situation as in our study -, the
GFU group was less expensive than the usual care
group. This conclusion only changed when the duration
of a visit in the usual care group would be relatively
short (7 minutes) and the duration of a visit in the GFU
group would be relatively long (24 minutes, scenario
1d). In that unlikely situation the hospital costs per
patient year were 10% higher for the GFU group (see
Table 6).
Analysis 2: duration HFA/GDX
The norm durations of GDx and HFA as used by the
financial department, were 15 and 45 minutes respec-
tively instead of 13.30 and 34.20 minutes. This longer
duration of the HFA and GDx tests increased the hospi-
tal costs per patient year in the GFU group and usual
care group with €15 and €12 respectively (Table 6).
Analysis 3: no optometrist in GFU
When the direct personnel costs of the optometrist were
replaced by those of the ophthalmic technicians, the
costs in both groups decreased, because incidentally a
visit was paid to an optometrist in the usual care group
as well (Table 6). Although the decrease in costs per
patient year is small, it is almost twice as high in the
Table 5 Average costs in Euros per patient year per perspective used for the two treatment groups (SD)
GFU Usual Care P-value
Hospital perspective
Hospital visits (including GDx ECC) 111.93 (50.93) 133.17 (50.44) 0.000
Other tests (HFA, refraction, pachymetry, etc.) 20.66 (47.03) 24.18 (48.72) 0.001
Laser treatment related to glaucoma 0.18 (2.54) 0.57 (5.18) 0.258
Glaucoma surgery 2.84 (40.35) 1.72 (34.90) 0.558
Asking advice 3.24 (5.35) 1.78 (5.13) 0.000
Total hospital costs per patient year 138.85 (89.30) 161.43 (86.88) 0.000
Patient perspective
Patient costs per visit
Travelling costs of patient and accompaniment 8.26 (11.83) 8.19 (12.10) 0.966
Time costs of patient and accompaniment 40.58 (28.87) 47.51 (34.36) 0.000
Total patient costs per patient per visit 48.83 (33.68) 55.70 (37.88) 0.000
Patient costs per patient year
Travelling costs of patient and accompaniment 13.04 (17.16) 12.70 (17.87) 0.488
Time costs of patient and accompaniment 66.62 (50.20) 75.17 (61.37) 0.088
Total patient costs per patient year 79.66 (58.51) 87.87 (68.17) 0.143
Health care perspective
Hospital costs 138.85 (89.30) 161.43 (86.88) 0.000
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867
Total health care costs per patient year 230.39 (154.57) 251.26 (146.02) 0.004
Societal perspective
Hospital costs 138.85 (89.30) 161.43 (86.88) 0.000
Patient costs 79.66 (58.51) 87.87 (68.15) 0.143
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867
Total societal costs per patient year 310.05 (181.86) 339.13 (180.39) 0.009
SD = Standard Deviation; GFU = Glaucoma Follow-up Unit; GDx ECC = Nerve Fiber Analyser Enhanced Corneal Compensation; HFA = Humphrey Field Analyser.
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GFU group (€3.69) as in the usual care group (€1.96).
Thus, the costs remain lower for the GFU group.
Analysis 4: fewer specialist visits in GFU
a. In this scenario, the total savings were €2193 for five
visits of 427 patients. Based on a mean number of 1.65
visits per year as measured in this study, the hospital
costs could be reduced with €1.69 per patient year.
b. In the second scenario, the total savings in visit
costs were €1882 for five visits of 427 patients, thereby
reducing the hospital costs in the GFU group with €1.45
per patient year (= 1%).
Uncertainty analysis
From a societal perspective, the incremental cost-effec-
tiveness ratio of the GFU compared with usual care
was - €27 per patient per decimal point increase of the
patients’ overall mark (on a 1-10 scale) per year. The
CE-plane with overall mark as outcome showed that
the majority of bootstrap replications (70%) fell within
the lower-right quadrant, indicating that the GFU was
dominant with lower costs and a higher overall mark
(Figure 2a).
The incremental cost-effectiveness ratio for the GFU
compared with usual care was + €19 per patient per
year for one extra percent of visits that were considered
to be stable by the practitioner. For the CE-plane with
“stability” as outcome, the majority of bootstrap replica-
tions fell within the lower-left quadrant which reflects
lower costs and fewer stable visits (Figure 2 b). The
probability that the GFU is cost saving is 89% using the
overall mark and 84% using the “stability” outcome.
Against this high probability of saving costs, the prob-
ability of inferiority of the GFU (being more expensive
and less effective) is quite small: 2% using the overall
mark and 14% using the “stability” outcome.
Using an acceptable difference of 0.5 point of the
overall mark (range 1-10), and of 5% difference in the
fraction of stable patients, the two groups have an equal
quality of care in 99.5% and 80.5% of the bootstrap
replications respectively. When including replications
that result in a better quality of life for the GFU, the
quality of care is acceptable (equal or better) in 100%
and in 83.6% of the bootstrap replications.
Discussion
Substitution of tasks that require less specialized skills is
a possible solution for easing the increased workload of
ophthalmologists and long waiting lists in ophthalmic
care. It was hypothesized that task substitution reduces
the costs as well. The monitoring of most stable glau-
coma patients probably does not require specialized
skills. In this study, we therefore compared the care as
usual provided by glaucoma specialists with the care
provided by a GFU within the REH staffed by ophthal-
mic technicians and optometrists for stable glaucoma
patients.
We found about 10% lower health care costs per
patient year for the GFU group compared to the usual
care group for three of the four perspectives used: the
REH, the health care system and the society. Patient
costs did not differ between the two treatment groups.
Scenario and sensitivity analyses confirmed that our
results were robust. Only if the mean duration of a visit
increased in the GFU (with 18% to the maximum dura-
tion measured in this study) and decreased for the glau-
coma specialist (with 23% to the minimum duration
measured in our study, scenario 1d), would the total
societal costs not be significantly different any longer.
However, this situation is not realistic. The bootstrap
analysis showed that the equivalence of the two groups
on quality of care is justified and that the GFU is cost
saving in 89% of the bootstrap replicates when using the
overall mark as outcome parameter and in 84% of the
replicates when using the stability of the patient accord-
ing to the practitioner.
We hypothesized that the establishment of the GFU
would reduce the waiting list. This was confirmed by
the increased number of patients (+23%) and patient
visits (+16%) per year within the study period. The
increased number of visits was largely caused by the
establishment of the GFU, whereas the rise in the num-
ber of glaucoma patients was also influenced a little by
a reduced follow-up interval for some glaucoma
patients. However, the long term effect on the waiting
list seems to be limited. Possible causes are: the chronic
character of the disease which limits the patient outflow
and the substantial increase in new glaucoma patients
that outweighs the growth in capacity. Further research
would be necessary to explore the true cause(s).
The hospital perspective was one of the perspectives
used for the cost calculation. Although the probability
that the GFU is cost-effective from this perspective is
94-98%, we have to distinguish at least two stakeholders
within the hospital; the hospital management and the
glaucoma specialists. The interests of those two
Table 6 Total average hospital costs per patient year in
Euros for all situations in the sensitivity/scenario analysis
Hospital costs
GFU Usual care
Base case 138.85 161.43
Scenario 1a 117.79 141.80
Scenario 1b 156.79 179.98
Scenario 1c 117.79 179.98
Scenario 1d 156.79 141.80
Scenario 2 153.78 173.18
Scenario 3 135.16 159.47
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stakeholders are partially conflicting due to the current
structure of financing care in the Netherlands. The phy-
sician part of the reimbursement is now paid to the spe-
cialist although the monitoring is partially transferred to
the GFU. The distribution of this fee will therefore
become subject of discussion between glaucoma specia-
lists and the hospital management, especially when
health care insurers insist on a lower fee in future nego-
tiations, because of the lower costs of monitoring glau-
coma patients by the GFU.
Our results could not be easily compared with results
of other research. Even though substituting tasks within
the hospital setting is taking place, a full cost calculation
of this kind of substitution in the ophthalmic care has
not been performed yet. In Bristol (UK), an economic
evaluation alongside an RCT has been performed, com-
paring costs of monitoring stable glaucoma patients by
ophthalmologists and community optometrists (outside
the hospital). [2,6] Contrary to ours, the UK study con-
cluded that the substitution of care to community opto-
metrists was not likely to save costs. The main reason
for this was the larger number of referrals to the
ophthalmologist in their study compared to ours (19%
vs. 6%). An explanation for this difference might be the
location of care. Community optometrists do not have
the possibility to consult a specialist for quick advice
and will therefore refer patients to the hospital relatively
more often.
Furthermore, the frequency of visits to the community
optometrist in Bristol was 66% higher than the visit fre-
quency to the ophthalmologist, compared with a 5%
higher frequency in our study. This difference is related
to a difference in the protocol used. In our study, the
time to the next visit was copied from the last visit to
the glaucoma specialist instead of being pre-determined
at 6 months.
A study about the trends in outpatient care provided
by physicians and non-physician clinicians showed that
substitution of care is not always a good strategy for
containing health care costs. [22] The increase in the
proportion of patients visiting a non-physician clinician
is driven by the increase in patients visiting both a non-
physician and a physician clinician. In our study how-
ever, the number of extra visits caused by referrals was
relatively low as stated earlier.
A possible drawback of our study is the lack of infor-
mation about disease progression. The progression rate
of glaucoma depends on the intraocular pressure, and
the time to vision loss varies between 3 years for
untreated patients with a high intraocular pressure to 38
years for well treated patients. [23,24] We therefore did
not expect to detect any significant glaucomatous pro-
gression in the 30-months study period in these stable
patients and performed a cost minimization study. This
type of economic evaluation assumes an equal outcome
for all patients. The results of the RCT [7] as well as
many other studies [3,4,8-18] supported this assumption
about the equal quality of care to glaucoma patients
provided by different types of health care providers.
Conclusions
Considering the equal quality of care in both treatment
groups, we conclude that monitoring of glaucoma
patients by the GFU is cost-effective for a subset of
glaucoma patients, i.e., those that were deemed stable in
the Rotterdam Eye Hospital. Implementation of a similar
GFU in other hospitals could therefore be considered.
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